NSG BioLabs partners with EnterpriseSG and Merck to boost biotech industry

It also secured US$14.5m in strategic funding.

NSG BioLabs, Singapore’s premier provider of biotech laboratory and office space, has teamed up with Enterprise Singapore (EnterpriseSG) and Merck to propel the biotech sector.

The partnerships aim to provide essential resources like funding, expertise, and networks to support startup research and development.

Additionally, NSG BioLabs has secured a US$14.5m financing round, led by Celadon Partners and ClavystBio.

Since 2019, NSG BioLabs has been instrumental in assisting over 40 companies, including multinationals and startups, in achieving significant milestones and securing nearly US$400m in funding.

“NSG BioLabs is committed to supporting innovators and proud to have helped in Singapore's growing biotech ecosystem,” said Daphne Teo, CEO and Founder of NSG BioLabs. “Our partnerships with EnterpriseSG and Merck signify the importance of a collaborative spirit, and we hope to spur greater collaboration among other stakeholders to benefit the biotech industry in Singapore and the Asia Pacific region.”

The renewed partnership with EnterpriseSG will focus on nurturing high-potential biotech startups, particularly in precision medicine, whilst the collaboration with Merck will provide NSG BioLabs residents with special access to reagents, equipment, and expertise.